Literature DB >> 3163381

Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex.

K Henry1, B J Chinnock, R P Quinn, C V Fletcher, P de Miranda, H H Balfour.   

Abstract

Zidovudine was present in the semen and serum of six patients with acquired immunodeficiency syndrome or the related complex who were receiving 200 mg of the drug orally every four to six hours. Mean semen zidovudine levels (as measured by a new radioimmunoassay) in samples collected 0.75 to 1.25 hours after oral dosing were 3.63 to 7.19 mumol/L. Levels in semen samples collected 3.0 to 4.5 hours after oral dosing were 1.68 to 6.43 mumol/L. These values are above the in vitro minimum inhibitory concentration for the human immunodeficiency virus type 1 (HIV-1). Mean serum concentrations at the early and late times after oral dosing were 0.22 to 3.07 mumol/L and 0.10 to 1.42 mumol/L, respectively. Ratios of semen/serum zidovudine levels ranged from 1.3 to 20.4. It is possible that a pH-dependent trapping mechanism, which has been described in the prostate for other antibiotics, was responsible for the relatively high semen levels observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163381

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

Review 2.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy.

Authors:  J K Ball; T Rowe; R Curran; W L Irving; G M Beards; G Sontag; M Youle; G Moyle; D Pillay
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

6.  Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Authors:  H L Jordan; A S Pereira; M S Cohen; A D Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.

Authors:  R M van Praag; S Repping; J W de Vries; J M Lange; R M Hoetelmans; J M Prins
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 8.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

Review 9.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 10.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.